Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Lucid Diagnostics Inc.NASDAQ: LUCD
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $108K, compared with -$412K a year earlier. Trailing-twelve-month accounts payables was $250K. Over 3 fiscal years it compounded at -15.3% a year.
Context
- Accounts payables amounted to 5.7% of revenue in FY2025, up 3.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $108K or moves back toward the trailing-twelve-month quarterly average of $62.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (270K) USD
- Year-over-year change
- -381.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (270K) | -381.3% |
| FY2024 | 2024-12-31 | 96K | +7.9% |
| FY2023 | 2023-12-31 | 89K | +120.0% |
| FY2022 | 2022-12-31 | (445K) | +33.1% |
| FY2021 | 2021-12-31 | (665K) | — |
Accounts Payables vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's LTM Mar 2026 accounts payables of $250K is the smallest of the 10 companies compared; the peer median is $951K.
- Its year-over-year change of +278.6% is the 4th highest of 10, against a peer median of +38.0%.
- Accounts payables amounts to 4.9% of revenue for LUCD, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.68M | +109.8% | +67.2% | 69.9% | |
| LTM Mar 2026 | $2.03M | +38.0% | +2.5% | 5.9% | |
| LTM Mar 2026 | $1.93M | -198.4% | — | 12.8% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $1.88M | +559.7% | — | 15.7% |
| LTM Mar 2026 | $1.37M | -139.9% | +113.5% | 1.9% | |
| LTM Mar 2026 | $1.33M | +472.5% | — | 334.6% | |
| LTM Mar 2026 | $951K | -76.2% | — | 0.9% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $887K | +2749.0% | — | 47.9% |
| LTM Mar 2026 | $275K | +34.1% | +74.3% | 0.5% | |
| LTM Mar 2026 | $250K | +278.6% | -15.3% | 4.9% | |
| Peer median (excluding LUCD) | $951K | +38.0% | +70.8% | 12.8% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Depreciation & Amortization | 4K | 1.94M | 2.5M | 1.17M | 872K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.6M | 14.99M | 6.82M | 4.53M | 4.49M |
| Change in Working Capital | 807K | 8.91M | 5.68M | (4.43M) | (2.81M) |
| Accounts Receivables | (200K) | 183K | (28K) | 0 | (601K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (665K) | (445K) | 89K | 96K | (270K) |
| Other Working Capital | 1.67M | 9.17M | 5.61M | (4.53M) | (1.94M) |
| Other Non-Cash Items | 9.6M | 653K | 4.85M | 119K | 8.97M |
| Operating Cash Flow | (17.67M) | (29.69M) | (32.82M) | (44.14M) | (46.49M) |
| Capital Expenditures | (862K) | (908K) | (221K) | (646K) | (197K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.2M) | 0 | (350K) | 0 |
| Investing Cash Flow | (862K) | (4.11M) | (221K) | (646K) | (197K) |
| Debt Repayment | 0 | 0 | 10M | 18M | 360K |
| Common Stock Issued | 77.74M | 1.81M | 284K | 451K | 58.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.66M) | 804K | 551K | 451K | 0 |
| Financing Cash Flow | 72.08M | 2.61M | 29.46M | 48.25M | 59.03M |
| Effect of Forex Changes | (255) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 53.54M | (31.18M) | (3.58M) | 3.46M | 12.35M |
| Free Cash Flow | (18.53M) | (30.59M) | (33.04M) | (44.79M) | (46.49M) |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.